Propanc Biopharma Publishes New Data: PRP Reprograms Chemotherapy-Resistant Pancreatic Cancer Cells & Restores Therapeutic Vulnerability
PRP pretreatment was tested before a chemotherapy challenge in pancreatic cancer cells with acquired chemotherapy resistance.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Propanc Biopharma (PPCB) announced preclinical findings showing its PRP candidate altered chemotherapy-resistant pancreatic cancer cells and supported subsequent chemotherapy sensitivity. In resistant-cell models, PRP reduced proliferation by ~50–54% and long-term colony-forming survival by up to 59%. Invasive capacity fell 47–81%, alongside changes toward a more epithelial, less migratory cell state.
A separate peer-reviewed pilot study reported an 85.9% reduction in mean tumor weight at the higher dose in a pancreatic mouse model and ~50% tumor-weight inhibition in an ovarian model. Propanc plans a Phase 1b first-in-human study for Q1 2027, expected to enroll up to 50 patients with advanced solid tumors in Australia. Manufacturing, drug-level assay validation and clinical preparations are advancing. PRP holds FDA Orphan Drug Designation for pancreatic cancer.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate point. Forward-looking: it has not happened yet and may not happen.Propanc plans a Q1 2027 Phase 1b first-in-human study, expected to enroll up to 50 patients.
- Minor pointPRP reduced resistant pancreatic cancer cell proliferation by ~50–54% in preclinical testing.
- Minor pointPRP suppressed long-term colony-forming survival by up to 59% in preclinical testing.
- Minor pointPRP reduced invasive capacity by 47–81% in resistant pancreatic cancer cell models.
- Minor pointCell migration reached 21–57% wound closure, versus 100% in untreated controls.
12 minor points
- Minor pointEpithelial markers increased: E-cadherin up to 5.29-fold and EPCAM up to 4.39-fold.
- Minor pointMesenchymal markers decreased: Vimentin to ~0.31–0.32-fold and Snail to 0.28–0.62-fold.
- Minor pointPRP downregulated TGF-β/SMAD signaling, a cellular signaling pathway, in preclinical testing.
- Minor pointCell-death-promoting BAX increased up to 2.74-fold in preclinical testing.
- Minor pointMYC and SOX2, drivers of stem-like properties, fell to 0.11–0.22-fold in resistant cells.
- Minor pointPRP plus TGF-β inhibition produced 80% invasion inhibition and stronger cell-death signaling.
- Minor pointPeer-reviewed pancreatic mouse-model results showed 85.9% lower mean tumor weight at the higher PRP dose.
- Minor pointPeer-reviewed ovarian-model results showed ~50% tumor-weight inhibition.
- Minor pointThe peer-reviewed pilot study also showed anti-angiogenic activity, limiting blood-vessel formation, and near-complete invasion blockade in select lines.
- Minor pointEarlier advanced pancreatic cancer models showed >90% mean tumor growth inhibition and reduced metastatic burden.
- Minor pointEarlier advanced pancreatic cancer models showed >2.5-fold median survival extension.
- Minor pointPRP holds FDA Orphan Drug Designation for pancreatic cancer.
Negative
- None.
Key Figures
- Cancer cell proliferation reduction
- ~50–54%
- PRP monotherapy in preclinical models
- Clonogenic survival reduction
- up to 59%
- PRP monotherapy in preclinical models
- Invasive capacity reduction
- 47–81%
- Preclinical pancreatic cancer models
- E-cadherin upregulation
- up to 5.29-fold
- Preclinical EMT reversal findings
- Invasion inhibition
- 80%
- PRP plus TGF-β inhibition
- Planned Phase 1b study
- Q1 2027
- First-in-human study timing
- Planned enrollment
- up to 50 patients
- Phase 1b study of advanced solid tumors
Historical Context
-
Earlier release disclosed resistant-cell proliferation reduction and 80% invasion inhibition with PRP combinations.
-
Peer-reviewed pilot reported 85.9% pancreatic-model tumor-weight reduction and roughly 50% ovarian-model inhibition.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
emt medical
syngeneic medical
orphan drug designation regulatory
pharmacokinetics medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Peer-Reviewed Scientific Reports Data & Academic Collaboration Show Potent Anti-Tumor Activity, EMT Reversal, & Sequential Chemo-Sensitization; Phase 1b First-In-Human Study Planned for Q1 2027
MELBOURNE, Australia, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases including recurrent and metastatic cancer, today announced new preclinical data supporting the potential of its lead asset, PRP (a proprietary fixed-ratio 1:6 intravenous formulation of trypsinogen and chymotrypsinogen), to address chemotherapy resistance in pancreatic cancer.
In collaborative research led by Dr. Maria Belén Toledo at the Universities of Jaén and Granada, PRP was shown to remodel the resistant cellular state in pancreatic cancer models with acquired chemotherapy resistance. The study used a sequential design (chemoresistant cells → PRP pre-treatment → chemotherapy challenge) and demonstrated that PRP functions as a resistance-modulating intervention rather than a conventional cytotoxic agent. Key preclinical findings:
- Proliferation and survival: PRP monotherapy reduced cancer cell proliferation by ~50–
54% and suppressed long-term clonogenic survival by up to59% . - Metastatic behavior: Migration limited to 21–
57% wound closure (vs.100% in untreated controls); invasive capacity reduced by 47–81% . - EMT reversal: Strong epithelial differentiation with E-cadherin upregulated up to 5.29-fold and EPCAM up to 4.39-fold; mesenchymal drivers Vimentin reduced to ~0.31–0.32-fold and Snail to 0.28–0.62-fold.
- Pathway effects: Significant downregulation of TGF-β/SMAD signaling, induction of pro-apoptotic BAX (up to 2.74-fold), and suppression of oncogenic stemness drivers MYC and SOX2 (down to 0.11–0.22-fold in resistant cells).
- Combination synergy: PRP plus TGF-β inhibition further amplified responses, including
80% invasion inhibition and stronger apoptotic signaling.
These results complement the Company’s recent peer-reviewed pilot study published in Scientific Reports (Nature Publishing Group), which reported an
In addition, earlier orthotopic and patient-derived xenograft data have also shown >
In vivo anti-tumor activity of PRP
(A) Images of excised tumors at study termination of orthotropic pancreatic tumors. Mean tumor weight at termination day after daily I.V. injection of PBS, T/C 27.5/165 (mg/kg) or T/C 83.3/500 (mg/kg) (∗P < 0.05). (B) Images of excised tumors at study termination of orthotropic ovarian tumors. Mean tumor weight at termination day after daily I.V. injection of PBS, T/C 9.1/54 (mg/kg) or T/C 27.5/165 (mg/kg) (∗P < 0.05)
PRP’s differentiation-based mechanism—targeting cancer stem cells, EMT, fibrosis, and metastatic dissemination—is distinct from and potentially complementary to emerging RAS-targeted approaches. Revolution Medicines’ daraxonrasib (RASONQUE), recently FDA-approved for metastatic pancreatic adenocarcinoma, has set a clinical benchmark with median overall survival of 13.2 months versus 6.6–6.7 months for chemotherapy in the Phase 3 RASolute 302 trial. Erasca’s pan-RAS molecular glue ERAS-0015 similarly focuses on oncogenic RAS signaling. PRP does not inhibit RAS and is not genotype-restricted; its preclinical package of deep tumor control, fewer metastases, a less fibrotic microenvironment, and chemo re-sensitization, addresses residual biology that RAS pathway blockade does not directly target. Limited prior compassionate-use experience with related proenzyme formulations has shown signals of prolonged survival in advanced solid-tumor patients with a favorable safety profile. PRP holds FDA Orphan Drug Designation for pancreatic cancer.
“These findings are highly significant as we progress PRP to our world-first Phase 1b First-in-Human study for advanced solid-tumor patients planned for Q1 2027,” said Mr. James Nathanielsz, Propanc’s Chief Executive Officer. “We envision PRP as a long-term, metronomic therapy that minimizes the threat of recurrence while enabling patients to better respond to standard treatments when resistance becomes critical. The data positions PRP as a potential sequential or combination partner to RAS inhibitors from companies such as Revolution Medicines and Erasca, addressing biology—cancer stem cells, EMT, fibrosis, and metastatic spread—that those agents do not primarily target.”
The Company continues advancing manufacturing, pharmacokinetics assay validation, and clinical preparations for the multicenter, open-label Phase 1b study (dose escalation followed by expansion) expected to enroll up to 50 patients with advanced solid tumors, including pancreatic, ovarian, and refractory prostate cancers, at sites in Australia.
About Propanc Biopharma, Inc.
Propanc Biopharma, Inc. (Nasdaq: PPCB) is developing a novel approach to preventing cancer recurrence and metastasis by targeting and eradicating cancer stem cells through proenzyme activation. The Company’s lead product candidate, PRP, is designed to address the underlying drivers of cancer proliferation and spread.
More information: www.propanc.com
Forward-Looking Statements
All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to the Company’s expectations regarding its market position and market opportunity, expectations and plans as to its product development, manufacturing and sales, and relations with its partners and investors, made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are not historical facts but rather are based on the Company’s current expectations, estimates, and projections regarding its business, operations and other similar or related factors. Words such as “may,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expect,” “intend,” “plan,” “project,” “believe,” “estimate,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond the Company’s control. Forward-looking statements are not guarantees of future actions or performance. Actual results may differ materially from those in the forward-looking statements because of several factors, including, without limitation, risks and uncertainties related to market conditions, as well as those risks described under “Risk Factors” in the prospectus related to the proposed offering and those described in the Company’s filings with the SEC. The Company undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available.
Company:
Propanc Biopharma, Inc.
James Nathanielsz
+61-3-9882-0780
info@propanc.com
Investor Contact:
irteam@propanc.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Propanc's PRP study show in chemotherapy-resistant pancreatic cancer cells?
PRP reduced proliferation by ~50–54% and long-term colony-forming survival by up to 59% in preclinical resistant-cell models. The experiment treated chemotherapy-resistant cells with PRP before a chemotherapy challenge and demonstrated resistance modulation rather than conventional direct cell killing.
When does Propanc plan to begin PRP's first-in-human study?
Propanc plans its Phase 1b first-in-human study for Q1 2027. The study is expected to enroll up to 50 patients with advanced solid tumors at Australian sites. Manufacturing, drug-level assay validation and clinical preparations are advancing.
How will Propanc's planned PRP Phase 1b trial be designed?
The planned trial is a multicenter, open-label study with dose escalation followed by expansion. Open-label means treatment assignments are known. Eligible disease groups are expected to include pancreatic, ovarian and refractory prostate cancers.